A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of SHEN26 Capsule in Adult Participants With Mild to Moderate COVID-19

This is a multicenter, randomized, double-blind, placebo-parallel-controlled phase III clinical trial. It is designed to evaluate the efficacy and safety of SHEN26 capsules in Chinese adult patients with mild to moderate COVID-19

开始日期2023-05-13

申办/合作机构

深圳科兴药业有限公司

100 项与肾炎舒胶囊相关的临床结果

登录后查看更多信息

100 项与肾炎舒胶囊相关的转化医学

登录后查看更多信息

100 项与肾炎舒胶囊相关的专利（医药）

登录后查看更多信息

项与肾炎舒胶囊相关的文献（医药）

2023-11-01·Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica

[Network Meta-analysis of efficacy of seven Chinese patent medicines in treatment of inflammatory response in chronic glomerulonephritis].

Article

作者: Wang, Xi-Xi ; Zhang, Lin-Qi ; Zhou, Xiao-Jie ; Yang, Kang ; Shi, Ruo-Yu ; Zhang, Ke-Xin

This study aimed to evaluate the efficacy and safety of various Chinese patent medicines in the treatment of inflammatory response in chronic glomerulonephritis(CGN) based on network Meta-analysis. Randomized controlled trial(RCT) of oral Chinese patent medicines for improving inflammatory response in patients with CGN was retrieved from databases such as CNKI, Wanfang, VIP, SinoMed, PubMed, Cochrane Library, EMbase, and Web of Science from database inception to March 2023. All investigators independently screened the literature, extracted data, and evaluated the quality. Stata 16.0 and RevMan 5.4.1 software were used to analyze the data of the literature that met the quality standards. Finally, 71 RCTs were included, involving 7 Chinese patent medicines. The total sample size was 6 880 cases, including 3 441 cases in the test group and 3 439 cases in the control group. The network Meta-analysis showed that(1) in terms of reducing TNF-α, the top 3 optimal interventions according to the surface under the cumulative ranking curve(SUCRA) were Shenyanshu Capsules/Granules/Tablets+conventional western medicine, Huangkui Capsules+conventional western medicine, and Bailing Capsules+conventional western medicine.(2) In terms of reducing hs-CRP, the top 3 optimal interventions according to SUCRA were Yishen Huashi Granules+conventional western medicine, Huangkui Capsules+conventional wes-tern medicine, and Bailing Capsules+conventional western medicine.(3) In terms of reducing IL-6, the top 3 optimal interventions according to SUCRA were Yishen Huashi Granules+conventional western medicine, Bailing Capsules+conventional western medicine, and Shenyan Kangfu Tablets+conventional western medicine.(4) In terms of reducing 24hUTP, the top 3 optimal interventions according to SUCRA were Shenyan Kangfu Tablets+conventional western medicine, Bailing Capsules+conventional western medicine, and Huangkui Capsules+conventional western medicine.(5) In terms of reducing Scr, the top 3 optimal interventions according to SUCRA were Bailing Capsules+conventional western medicine, Shenyanshu Capsules/Granules/Tablets+conventional western medicine, and Yishen Huashi Granules+conventional western medicine.(6) In terms of reducing BUN, the top 3 optimal interventions according to SUCRA were Yishen Huashi Granules+conventional western medicine, Shenyanshu Capsules/Granules/Tablets+conventional western medicine, and Bailing Capsules+conventional western medicine.(7) In terms of improving the clinical total effective rate, the top 3 optimal interventions according to SUCRA were Huangkui Capsules+conventional western medicine, Kunxian Capsules+conventional western medicine, and Yishen Huashi Granules+conventional western medicine. The results showed that the combination of conventional western medicine and Chinese patent medicine could reduce the expression of serum inflammatory factors TNF-α, hs-CRP, and IL-6 and inhibit the inflammatory response. The combination of conventional western medicine and Chinese patent medicine was superior to conventional western medicine alone in reducing Scr, BUN, and 24hUTP, and improving the clinical total effective rate of treatment. Due to the limitation of the quantity and quality of literature included, the above conclusions need to be validated by more high-quality studies.

项与肾炎舒胶囊相关的新闻（医药）

2022-11-18

·蒲公英Ouryao

药典委：肾炎舒胶囊、通脉降脂胶囊等4个标准草案公示

来源：药典委整理：wangxinglai2004 2022年11月18日，国家药典委发布了4则标准公示通知，涉及品种分别为肾炎舒胶囊、康寿丸、通脉降脂片和通脉降脂胶囊，公示期同为3个月。01 肾炎舒胶囊我委拟修订肾炎舒胶囊国家药品标准，标准编号：WS3-136（Z-136）-2002Z，为确保标准的科学性、合理性和适用性，现将拟修订的肾炎舒胶囊国家药品标准公示征求社会各界意见（详见附件）。公示期自发布之日起3个月。请认真研核，若有异议，请及时来函提交反馈意见，并附相关说明、实验数据和联系方式。相关单位来函需加盖公章，个人来函需本人签名，同时将电子版发送至指定邮箱。联系人：赵宇新，倪龙电话：010-67079523，010-67079592 电子邮箱：zy@chp.org.cn 通信地址：北京市东城区法华南里11号楼国家药典委员会办公室邮编：100061 02 康寿丸我委拟修订康寿丸国家药品标准，标准编号：WS3-B-2231-96)。为确保标准的科学性、合理性和适用性，现将拟修订的康寿丸国家药品标准公示征求社会各界意见（详见附件）。公示期自发布之日起三个月。请认真研核，若有异议，请及时来函提交反馈意见，并附相关说明、实验数据和联系方式。相关单位来函需加盖公章，个人来函需本人签名，同时将电子版发送至指定邮箱。联系人：郝博，申明睿电话：010-67079590，010-67079532 电子邮箱：zy@chp.org.cn 通信地址：北京市东城区法华南里11号楼国家药典委员会办公室邮编：10006103 通脉降脂胶囊我委拟修订通脉降脂胶囊国家药品标准，标准编号：WS-10472（ZD-0472）-2002-2011Z。为确保标准的科学性、合理性和适用性，现将拟修订的通脉降脂胶囊国家药品标准公示征求社会各界意见（详见附件）。公示期自发布之日起3个月。请认真研核，若有异议，请及时来函提交反馈意见，并附相关说明、实验数据和联系方式。相关单位来函需加盖公章，个人来函需本人签名，同时将电子版发送至指定邮箱。联系人：赵宇新，倪龙电话：010-67079523，010-67079592 电子邮箱：zy@chp.org.cn 通信地址：北京市东城区法华南里11号楼国家药典委员会办公室邮编：10006104 通脉降脂片我委拟修订通脉降脂片国家药品标准，为确保标准的科学性、合理性和适用性，现将拟修订的通脉降脂片国家药品标准公示征求社会各界意见（详见附件）。公示期自发布之日起3个月。请认真研核，若有异议，请及时来函提交反馈意见，并附相关说明、实验数据和联系方式。相关单位来函需加盖公章，个人来函需本人签名，同时将电子版发送至指定邮箱。联系人：赵宇新，倪龙电话：010-67079523，010-67079592 电子邮箱：zy@chp.org.cn 通信地址：北京市东城区法华南里11号楼国家药典委员会办公室邮编：100061

申请上市

100 项与肾炎舒胶囊相关的药物交易

登录后查看更多信息